No connection

Search Results

ALT vs PRTC

ALT
Altimmune, Inc.
BEARISH
Price
$3.50
Market Cap
$438.3M
Sector
Healthcare
AI Confidence
85%
PRTC
PureTech Health plc
NEUTRAL
Price
$18.30
Market Cap
$445.5M
Sector
Healthcare
AI Confidence
75%

Valuation

P/E Ratio
ALT
--
PRTC
10.7
Forward P/E
ALT
-2.59
PRTC
-36.6
P/B Ratio
ALT
1.73
PRTC
1.17
P/S Ratio
ALT
10690.5
PRTC
69.7
EV/EBITDA
ALT
-2.3
PRTC
-36.48

Profitability

Gross Margin
ALT
0.0%
PRTC
0.0%
Operating Margin
ALT
-111127.0%
PRTC
-2589.52%
Profit Margin
ALT
0.0%
PRTC
792.96%
ROE
ALT
-50.57%
PRTC
9.44%
ROA
ALT
-28.17%
PRTC
-12.95%

Growth

Revenue Growth
ALT
420.0%
PRTC
542.7%
Earnings Growth
ALT
--
PRTC
--

Financial Health

Debt/Equity
ALT
0.16
PRTC
0.44
Current Ratio
ALT
18.55
PRTC
8.49
Quick Ratio
ALT
18.35
PRTC
8.35

Dividends

Dividend Yield
ALT
--
PRTC
--
Payout Ratio
ALT
0.0%
PRTC
0.0%

AI Verdict

ALT BEARISH

ALT exhibits severe financial distress despite strong revenue growth, as evidenced by a Piotroski F-Score of 1/9—indicating poor operational and financial health. The Altman Z-Score is unavailable, but the company's negative profitability metrics (ROE: -50.57%, ROA: -28.17%), massive operating losses, and negative earnings suggest high distress risk. While revenue growth is explosive at 420% YoY, this is not translating into profitability or cash flow, and the stock trades at an extreme Price/Sales of 10,690.50, reflecting speculative valuation. Analysts recommend 'buy' with a $17.22 target, but this is likely driven by pipeline optimism rather than fundamentals. The technical trend is bearish, and insider activity is neutral, offering no conviction.

Strengths
420% YoY revenue growth indicates strong top-line momentum
High average earnings surprise (+8.52%) in recent quarters suggests potential for upside in earnings execution
Strong current and quick ratios (18.55 and 18.35) indicate exceptional short-term liquidity
Risks
Piotroski F-Score of 1/9 signals extreme financial weakness and poor operational efficiency
Negative ROE (-50.57%) and ROA (-28.17%) reflect deep unprofitability and capital inefficiency
Operating margin of -111,126.92% indicates massive operational losses relative to revenue
PRTC NEUTRAL

PRTC presents a contradictory financial profile with a stable Piotroski F-Score of 5/9 and a strong liquidity position (Current Ratio 8.49), yet suffers from severe operational inefficiency. While the Graham Number of $24.47 suggests defensive value, the growth-based intrinsic value of $11.90 and a negative forward P/E indicate significant future earnings risk. The massive discrepancy between the reported profit margin (792.96%) and operating margin (-2589.52%) suggests the company is relying on non-operating gains rather than core business profitability. Short-term price momentum is positive, but long-term performance remains deeply depressed.

Strengths
Exceptional short-term liquidity with a Current Ratio of 8.49
Low leverage with a Debt/Equity ratio of 0.44
Explosive year-over-year revenue growth of 542.70%
Risks
Catastrophic operating margins (-2589.52%) indicating high cash burn
Negative forward P/E suggests expected losses in the coming year
Extremely high Price-to-Sales ratio (69.70) indicating overvaluation relative to revenue

Compare Another Pair

ALT vs PRTC: Head-to-Head Comparison

This page compares Altimmune, Inc. (ALT) and PureTech Health plc (PRTC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile